Overview

Safety and Efficacy Evaluation of BZ371A Topically Applied on Prostatectomized Patients

Status:
Not yet recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
To determine efficacy, safety and tolerabiltiy of topically applied BZ371A in patients that experienced RP, in combination with daily tadalafil compared to placebo.
Phase:
Phase 2
Details
Lead Sponsor:
Biozeus Biopharmaceutical S.A.
Treatments:
Tadalafil